New pharmacological agents for the treatment of gastroesophageal reflux disease

Reviews in Gastroenterological Disorders

Volumn 8, Issue 2, 2008, Pages 117-122

  Vakil, Nimish ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MARQUETTE UNIVERSITY   (United States)

Author keywords

Esophagitis; Gastroesophageal reflux disease; Lower esophageal sphincter; Proton pump inhibitors; Serotonergic receptors; TAK 390 MR

Indexed keywords

4 AMINOBUTYRIC ACID; 8 (2,6 DIMETHYLBENZYLAMINO) N (2 HYDROXYETHYL) 2,3 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; ACETYLCHOLINE; ANTACID AGENT; ATI 7505; AZD 3355; BACLOFEN; BENATOPRAZOLE; CANNABINOID DERIVATIVE; CHOLECYSTOKININ; CISAPRIDE; CS 526; GASTRIN ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; ILAPRAZOLE; LANSOPRAZOLE; LONG ACTING DRUG; NITRIC OXIDE; NON PRESCRIPTION DRUG; OMEPRAZOLE; OPIATE DERIVATIVE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; PUMOSETRAG; REVAPRAZAN; SEROTONIN 3 AGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN AGONIST; SORAPRAZAN; TAK 390; UNINDEXED DRUG; XP 19986;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESEARCH; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER; NONHUMAN; REVIEW; SIDE EFFECT; SOMNOLENCE; STOMACH ACID SECRETION; WEAKNESS;

ANTI-ULCER AGENTS; BENZAMIDES; CISAPRIDE; ESOPHAGEAL SPHINCTER, LOWER; GASTROESOPHAGEAL REFLUX; HUMANS; IMIDAZOLES; PROTON PUMP INHIBITORS; PYRIDINES; QUINUCLIDINES; RECEPTORS, SEROTONIN, 5-HT4;

EID: 46749089027     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Vakil N, van Zanten S, Kahrilas P, et al, and the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastoenterol. 2006;101:1900-1920.
2. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the Patient Unmet Needs Survey. J Clin Outcomes Manag. 2000;7:29-34.
3. Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol. 2006;101:18-28.
4. Carlsson R, Galmiche JP, Dent J, et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther. 1997;11:473-482.
5. + ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277-305.
6. Targownik LE, Metge C, Roos L, Leung S. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol. 2007;102:942-950. Epub 2007 Feb 21.
7. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998;12:1235-1240.
8. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000;14:709-714.
9. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998;12:1231-1234.
10. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267-1272.
11. Tonini M, Giorgio RD, Ponti FD. Novel therapeutic strategies in acid-related disorders. Expert Opin Ther Pat. 2003;13:639-649.
12. Lee RD, Vakily M, Wu J, Atkinson S. The effect and timing of food on the pharmacokinetics and pharmacodynamics of TAK-390 MR (Modified Release): evidence for dosing flexibility [abstract]. Am J Gastroenterol. 2007;102:S145. Abstract 78.
13. Zhang W, Wu J, Atkinson S. Pharmacokinetic, pharmacodynamic and safety evaluation of single and multiple 60 mg, 90 mg and 120 mg oral doses of modified release TAK-390MR and 30 mg oral doses of lansoprazole in healthy subjects [abstract]. Gastroenterology. 2007;132(suppl 2):A-487.
14. Wu J, Vakily M, Witt G, Mulford D. TAK-390MR vs lansoprazole for maintenance of drug concentration above a threshold which corresponds to higher % time p > 4 [abstract]. Am J Gastroenterol. 2007;102:S124. Abstract 15.
15. Sharma P, Shaheen N, Perez M, et al. TAK-390MR, a proton pump inhibitor with a novel dual delayed release (DDR) formulation, is highly effective in the healing of erosive esophagitis: data from randomized controlled trials [abstract S1073]. Gastroenterology. 2008;134:A-171.
16. Metz D, Howden C, Perez M, et al. TAK-390MR, a proton pump inhibitor with a novel dual delayed release formulation, maintains healing and controls heartburn in GERD patients with healed esophagitis [abstract S1074]. Gastroenterology. 2008;134:A-171.
17. Kim EJ, Lee RK, Lee SM, Kim DY. General pharmacology of IY-81149, a new proton pump inhibitor. Arzneimittelforschung. 2001;51:51-59.
18. Domagala F, Ficheux H, Houin G, Barré J. Pharmacokinetics of tenatoprazole, a newly synthesized proton pump inhibitor, in healthy male Caucasian volunteers. Arzneimittelforschung. 2006;56:33-39.
19. Kil BJ, Kim IW, Shin CY, et al. Comparison of 1Y81149 with omeprazole in rat reflux oesophagitis. J Auton Pharmacol. 2000;20:291-296.
20. Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PP1 with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol. 2005;100:1949-1956.
21. Thomson AB, Cohen P, Ficheux H, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther. 2006;23:1179-1187.
22. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology. 2000;119:1439-1446.
23. Neuhuber WL. Sensory vagal innervation of the rat esophagus and cardia: a light and electron microscopic anterograde tracing study. J Auton Nerv Syst. 1987;20:243-255.
24. Altschuler SM, Bao XM, Bieger D, et al. Viscerotopic representation of the upper alimentary tract in the rat: sensory ganglia and nuclei of the solitary and spinal trigeminal tracts. J Comp Neurol. 1989;283:248-268.
25. Rinaman L, Card JP, Schwaber JS, Miselis RR. Ultrastructural demonstration of a gastric monosynaptic vagal circuit in the nucleus of the solitary tract in rat. J Neurosci. 1989;9:1985-1996.
26. Torrealba F, Muller C. Ultrastructure of glutamate and GABA immunoreactive axon terminals of the rat nucleus tractus solitarius, with a note on infralimbic cortex afferents. Brain Res. 1999;820:20-30.
27. Blackshaw LA, Page AJ, Smid SD, et al. GABAB receptors-peripheral and central targets for controlling gastroesophageal reflux. Curr Opin CPNS Investig Drugs. 2000;2:333-343.
28. Lidums I, Lehmann A, Checklin H, et al. Control of transient LES relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology. 2000;118:7-13.
29. van Herwaarden MA, Samsom M, Rydholm H, Smout AJ. The effect of baclofen on gastrooesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther. 2002;16:1655-1662.
30. Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut. 2003;52:464-470.
31. Omari TI, Benninga MA, Sansom L, et al. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr. 2006;149:468-474.
32. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003;17:243-251.
33. Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52:1397-1402.
34. Castell DO, Gerson LB, Hirota WK, et al. R-baclofen prodrug XP19986 decreases reflux episodes and is well tolerated in GERD patients [abstract]. Gastroenterology. 2007;132:A-486.
35. AstraZeneca clinical trials. AstraZeneca Web site. Available at: http://www.astrazenecaclinicaltrials.com/article/519535.aspx. Accessed April 5, 2008.
36. Grider JR, Foxx-Orenstein AE, Jin JG. 5-hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestitie. Gastroenterology. 1998;115:370-380.
37. Pehlivanov N, Sarosiek I, Whitman R, et al. Effect of cisapride on nocturnal transient lower oesophageal sphincter relaxations and nocturnal gastro-oesophageal reflux in patients with oesophagitis: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2002;16:743-747.
38. Finizia C, Lundell L, Cange L, Ruth M. The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol. 2002;14:9-14.
39. ATI-7505 - Gastrointestinal Disorders. ARY Therapeutics Web site. Available at: http://www.aryx.com/wt/page/ati/7505. Accessed May 4, 2008.
40. Choung RS, Ferguson DD, Murray JA, et al. A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double-blind, placebo-controlled pharmacodynamic study. Aliment Pharmacol Ther. 2008;27:404-411.
41. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium competitive acid blocker (AZD 0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008;103:20-26.
42. Smart HL, James PD, Atkinson M, Hawkey CJ. Treatment of reflux oesophagitis with trimoprostil. Digestion. 1989;44:52-56.
43. Purushotham AD, Gray GR, Hansell DT. Prostaglandins in the treatment of reflux oesophagitis: double-blind placebo controlled clinical trial. J R Coll Surg Edinb. 1991;36:216-218.
44. Philadelphia Business Journal. Aphton files for bankruptcy, shares plunge. Available at: http://philadelphia.bizjoumals.com/philadelphia/stories/ 2006/05/22/daily17.html. Accessed April 5, 2008.